1. Medtech Insight
  3. >>Regulation

Hypertension Experts Push For New Trial Of Renal Denervation To Show Efficacy

 
• By Reed Miller

Since Medtronic’s sham-controlled SYMPLICITY HTN-3 trial of its Symplicity renal denervation device failed to meet its primary efficacy endpoint, manufacturers developing renal denervation systems have been working with researchers and FDA to map the next steps in researching and developing this hypertension therapy.

Companies developing renal denervation systems to treat hypertension are working together with FDA and hypertension experts to map out the future of the technology in the aftermath of the disappointing SYMPLICITY HTN-3 results.

SYMPLICITY HTN-3, the first major sham-controlled trial of renal denervation in patients with uncontrolled hypertension, showed that treatment with Medtronic’s Symplicity did not have a significantly greater effect on systolic blood pressure than a sham procedure in patients with systolic blood pressure over 160

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation